SEC Form 4 · accession 0001562180-17-000407
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mariam E Morris
Officer — Chief Financial Officer
Period of report
Jan 26, 2017
Accepted (ET)
Jan 30, 2017 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.87 | Jan 26, 2017 | A | 25,000 | A | — | Jan 25, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F18,333 of the shares underlying the option vested and became exercisable on the date of grant; 8,333 shares shall vest and become exercisable on the first anniversary of the date of grant, and 8,334 shares shall vest and become exercisable on the second anniversary of the date of grant, subject to the Reporting Person's continuous service with the Issuer on each such date.